AlphAIAlphAI — Financial news for AI agents
ocbj.com$GKOS

Glaukos Up 17% in After-Hours Following Record Q3 Results

Glaukos Corp. shares rose 17% in after-hours trading after reporting Q3 revenue of $211M, beating estimates of $168.8M. The company raised its 2026 net sales guidance to $775M-$785M. CEO Thomas Burns cited strong performance in iDose TR and Epioxa.

Original reporting
ocbj.com
Published Oct 28, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Glaukos Up 17% in After-Hours Following Record Q3 Results — source image
Source · ocbj.com
Decision brief

The 30-second read

$GKOSBullishHigh
01

Why it matters

The earnings beat and guidance raise provide a clear catalyst for short‑term upside, with the after‑hours surge indicating strong market appetite.

02

Market read

First‑report earnings with a sizable price move and guidance lift; high relevance for traders targeting biotech/medical‑device stocks.

03

What to watch

Potential supply‑chain constraints or reimbursement risks not discussed in the release.

Relevance 9/10Novelty 9/10Timing: after‑hours today

Background

Glaukos (NYSE:GKOS) is a publicly traded ophthalmic device company known for its iDose TR and Epioxa platforms.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Glaukos reported Q3 revenue of $211M, beating estimates, and raised 2026 sales guidance, triggering a 17% after‑hours price jump.

Expected impact

upward pressure as traders price in higher sales outlook

Evidence & confidence

Revenue beat, guidance lift, and immediate price reaction indicate fresh, material information.

Market effects

Sector

Positive signal for ophthalmic device sector, may lift peers.

Regional

U.S. biotech/medical device market sees fresh earnings-driven buying.

Global

Limited to niche medical device space, but adds optimism to global eye‑care innovation narrative.

Counterpoint

What could challenge this read

Some investors may question sustainability of rapid growth and valuation after a sharp move.

Key entities

  • Executive
    Thomas Burns

    Chairman and CEO of Glaukos, quoted on the results.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

4 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com